Clinical Trial Update: SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating subcutaneous versus intravenous isatuximab in combination with pomalidomide and dexamethasone for relapsed/refractory multiple myeloma;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory Multiple Myeloma

Drugs mentioned

• Decadron (Dexamethasone)
• Pomalyst (pomalidomide)
• SARCLISA (isatuximab)

Snippet

Sponsor: Sanofi | Conditions: Plasma Cell Myeloma Recurrent | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-11-14